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a  b  s  t  r  a  c  t
Proliferating  cell  nuclear  antigen  (PCNA)  is  an  essential  cofactor  for DNA  replication  and  repair,  recruiting
multiple  proteins  to their  sites  of  action.  We  examined  the  effects  of  the  PCNAS228I mutation  that  causes
PCNA-associated  DNA repair  disorder  (PARD).  Cells  from  individuals  affected  by PARD  are  sensitive  to the
PCNA inhibitors  T3  and T2AA,  showing  that  the  S228I  mutation  has consequences  for  undamaged  cells.
Analysis  of  the  binding  between  PCNA  and  PCNA-interacting  proteins  (PIPs)  shows  that  the  S228I  change
dramatically  impairs  the  majority  of  these  interactions,  including  that of Cdt1,  DNMT1,  PolD3p66 and
PolD4p12. In  contrast  p21 largely  retains  the  ability  to bind  PCNAS228I. This  property  is conferred  by the
p21  PIP box  sequence  itself,  which  is both  necessary  and  sufﬁcient  for PCNAS228I binding.  UbiquitinationCNA-associated repair disorder (PARD)
NA replication
NA repair
of PCNA  is unaffected  by  the S228I  change,  which  indirectly  alters  the structure  of the  inter-domain
connecting loop.  Despite  the  dramatic  in  vitro  effects  of  the  PARD  mutation  on PIP-degron  binding,  there
are only  minor  alterations  to the  stability  of p21  and  Cdt1  in cells  from  affected  individuals.  Overall
our  data  suggests  that  reduced  afﬁnity  of PCNAS228I for speciﬁc  clients  causes  subtle  cellular  defects  in
undamaged  cells  which  likely  contribute  to  the  etiology  of  PARD.
© 2017  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. Introduction
Accurate DNA replication is essential prior to cell division if
aughter cells are to inherit a genome free from mutation. The pro-
iferating cell nuclear antigen (PCNA) has a central role during DNA
eplication, acting to recruit enzymes to the DNA replication fork,
nd to modify enzymatic activity and processivity. At replication
ites PCNA recruits proteins required throughout the complex pro-
esses of chromosomal duplication, including (but not limited to):
NA polymerase delta (for lagging strand synthesis) [1], DNA lig-
se 1 (Lig1) and Flap endonuclease 1 (Fen1) (for Okazaki fragment
aturation) [2–4], RNaseH2B (for ribonucleotide removal) [5–7],
olymerase eta (Pol) (for translesion synthesis) [8], DNA methyl-
ransferase 1 (DNMT1) (for DNA methylation maintenance) [9],
nd chromatin assembly factor 1 (for chromatin assembly) [10,11].
CNA also regulates entry into S-phase via interactions with the
∗ Corresponding author.
E-mail address: catherine.green@well.ox.ac.uk (C.M. Green).
ttp://dx.doi.org/10.1016/j.dnarep.2016.12.003
568-7864/© 2017 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
cell cycle regulator p21 [12] and the pre-replication complex com-
ponent Cdt1 [13]. These PCNA partners all utilise a similar peptide
motif to associate with PCNA, the PCNA-interacting-protein (PIP)
box. This short motif interacts via a combination of charge-pair
and hydrophobic interactions with the interdomain connecting
loop (IDCL) of PCNA [14,15]. Proteins that bind PCNA in this man-
ner therefore compete for the same interaction surface, perhaps
to enable dynamic associations essential for progressing through
the multiple stages of chromosomal replication [16]. It has often
been postulated that PCNA might coordinate DNA replication, the
trimeric nature of PCNA lending itself to a “toolbelt model” where,
by binding multiple proteins sequentially, PCNA ensures appropri-
ate selection of enzymes at the replication fork [17]. However, this
model has recently been challenged by work showing that PCNA
with only a single interaction surface is still functional [18].
As well as its essential role in DNA replication, PCNA is also
required for DNA repair. PCNA is involved in the processes of
nucleotide excision repair (NER), long-patch base excision repair
(BER) and mismatch repair (MMR)  [16]. During these processes
PCNA interacts directly with repair proteins, including (but not
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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imited to): xeroderma pigmentosum A and G (XPA, XPG) (for
ER) [19,20], DNA glycosylases (UNG2 and MPG), endonucleases
APE1 and APE2) and polymerase beta [21–25] (for BER), and MutS
omologs 3 and 6 (for MMR)  [26]. It is also possible that PCNA is
equired for DNA repair synthesis during homologous recombina-
ion [27].
As PCNA is a crucial component of important pathways for
NA metabolism, it is not surprising that the encoding gene is
ssential in yeast and mice [28–30]. The gene is highly conserved
rom yeast to humans; S. cerevisiae,  S. pombe and M. musculus
CNAs are 35%, 51% and 97% identical to the human protein,
espectively [EMBOSS Needle]. Site-speciﬁc mutations of the S.
erevisiae protein result in a variety of phenotypes, including cold
ensitivity, sensitivity to DNA damaging agents and alterations to
elomere position effects [31–34]. In mice the only characterised
CNA variant is the site directed mutation of lysine-164 to argi-
ine, which results in infertility and in alterations to the somatic
ypermutation spectrum due to the requirement for ubiquitina-
ion on PCNA Lys164 for the recruitment of Pol [35]. The PCNA
rotein is not invariant in the human population, but its vari-
tion is very low. There are only seven missense coding SNPs
eported in the 1000 genomes browser (rs140522967, Ser223Pro;
s369958038, Ser228Ile; rs376351202, Met139Val; rs141842220,
la67Thr; rs144468297, Asn65Thr; rs1050525, Ser39Arg; and
s375496467, Val15Leu) all with minor allele frequencies of less
han 0.01 (where reported). Of these only one very rare allele
rs369958038, S228I) is reported pathogenic in the homozygous
tate [36]. We  previously described four individuals from the Ohio
mish population who are homozygous for this S228I sequence
lteration and affected by PCNA-associated DNA repair disorder
PARD), characterised by short stature, hearing loss, premature
ging, telangiectasia, neurodegeneration and photosensitivity [36].
 further PARD affected Amish individual from Wisconsin homozy-
ous for the same S228I founder mutation has since been identiﬁed,
he presented aged 4 years with short stature, sun sensitivity, pro-
ressive gait instability and hearing concerns. On examination,
here was no evidence of ocular or cutaneous telangiectasia, which
ppear to be a later manifestation of the disease.
We previously showed that PCNAS228I protein has altered bind-
ng to a number of client proteins, in particular XPG, Lig1 and
en1, and that cells from PARD affected individuals were more
ensitive to UV damage [36]. We here show data that PCNAS228I
lso causes repair independent consequences in cells from PARD
ffected inidividuals and present in-depth characterisation of the
rotein binding capability of PCNAS228I, showing that the effect
n binding varies signiﬁcantly across a range of PCNA interactors,
ependent on the sequence of the PIP-box. These consequences for
ellular functions will shed light on the complex pathology of this
isorder.
. Material and methods
.1. Cell lines
EBV transformed lymphoblastoid cell lines were established
rom four PARD affected individuals (1504, 1505, 1506, 1779)
nd two Amish wild type controls (0920, 0924) using the ser-
ice from Public Health England. Cell lines were maintained in
PMI with 10% FBS, 2 mM glutamine (Sigma), and 1% penicillin
nd streptomycin (PAA). Sensitivity of lymphoblasts to T2AA
37] (T2 amino alcohol ((S)-4-(4-(2-amino-3-hydroxylpropyl)-
,6-diiodophenoxyphenol)) and T3 (3,3′,5-triiodothyronine) was
etermined by addition of T2AA or T3 to 5 ml  cells at 2 × 105/ml
nd counting viable using trypan blue exclusion at indicated time
oints.pair 50 (2017) 22–35 23
2.2. Genotyping
Genotypes were conﬁrmed regularly for quality control
purposes. Genomic DNA was  extracted from lymphoblas-
toid cell lines using GenElute Mammalian Genomic DNA
Miniprep Kit as per manufacturer’s instructions. The genomic
region surrounding PCNA nucleotide position 683 was ampli-
ﬁed using standard PCR with Phusion
®
High Fidelity DNA
Polymerase (NEB, as per manufacturer’s instructions), using
the following primers 5′-ATAGCTCCCTCCAAAGTGACC-3′ and 5′-
CATCCTCGATCTTGGGAGCC-3′. Ampliﬁcation of a single band was
conﬁrmed by agarose gel electrophoresis and samples sequenced
by Sanger sequencing (GATC Biotech) using the primer 5′-
ACTAACTTTTGCACTGAGG-3′.
2.3. FACS analysis of cell cycle
Exponentially growing lymphoblastoid cells were incubated
with 10 M Bromodeoxy-uridine (BrdU) for 30 min  then cen-
trifuged (1000g, 5 min) and ﬁxed in 4% paraformaldehyde (PFA),
20 min. Cells were washed in PBS, treated with 0.2 mg/mL pepsin
in 2 M HCl, 20 mins, then probed with anti-BrdU (1:50, 347580, BD)
1 h in PBS with 1% BSA and 0.5% Tween 20 with intervening washes
with PBS. Cells were washed in PBS with 1% BSA, 0.5% Tween 20 and
incubated with Alexa Fluor 633 anti-mouse (1:200, Invitrogen) for
1 h. Cells were washed as before, incubated in PBS with 0.5 mg/mL
RNase A overnight at 4 ◦C and stained with 10 g/mL propidium
iodide before analysis using a CyAn ADP Analyzer (Beckman Coul-
ter).
2.4. Cell manipulations
For analysis of PIP degrons, exponentially growing lymphoblasts
were treated with indicated levels of 254 nm UVC light in PBS. Cells
were allowed to recover in growth medium for the indicated times,
then harvested at 4 ◦C for protein analysis. Samples were prepared
in Benzonase buffer (25 mM NaCl, 50 mM HEPES pH 7.8, 0.05% SDS,
4 mM MgCl2, 5x cOmplete EDTA free Protease Inhibitor Cocktail
Tablets (Roche), 0.5% Benzonase (Novagen)) with incubation on ice
for 10 mins. Protein levels were adjusted by dilution using Bradford
Reagent and 4x Laemmli added, 95 ◦C, 5 mins. Proteins were sepa-
rated on SDS-PAGE gels and transferred to 0.2 m nitrocellulose.
2.5. Antibodies
The following primary antibodies were used for western
blotting mouse anti-actin (A4700, Sigma Aldrich), PCNA (PC10,
Millipore), rabbit anti-Cdt1 (D10F11, Cell Signalling Technology),
DNMT1 (NB100-56519, Novus Biologicals), Fen1 (EPR4459(2),
GeneTex), Ligase I (PA5-27820, Thermo Scientiﬁc), p21 (EPR362,
abcam), Pol (ab17725, abcam), Ubiquitinated-PCNA (D5C7P, Cell
Signalling Technology).
2.6. Mass spectrometry
HEK293 stably expressing StrepTagII V5 PCNAWT or empty vec-
tor control were made using pEXP pcDNA3.1/StrepTagII V5 PCNAWT
generated from pcDNA3.1/nV5-DEST (ThermoFisher) with Strep-
TagII inserted at HinDIII site and PCNA inserted by LR reaction
(ThermoFisher). Stable clones were selected with Neomycin and
selected for level of exogenous PCNA expression by western blot.
Cells were cultured and lysates collected in extract buffer (0.5%
Igepal, 40 mM NaCl, 50 mM Tris pH 7.5, 2 mM MgCl2, 2x cOm-
plete Protease Inhibitor Cocktail Tablets (Roche), 1x phosphatase
inhibitor (Roche), 0.1% Benzonase (Novagen)) on ice, 10 min. NaCl
was increased to 150 mM with 20 min  incubation, 4 ◦C and lysates
2 NA Re
c
d
S
1
I
b
r
a
4
g
e
o
5
i
a
L
d
3
a
c
f
f
t
m
P
2
d
p
w
P
t
i
a
A
s
0
G
S
t
f
p
u
b
g
p
U
m
f
f
y
2
p
I
v
4
e
a
a
e
N4 R.H.C. Wilson et al. / D
leared 21000 g, 4 ◦C, 20 min. Protein concentrations were stan-
ardised using Bradford assay then incubated with Strep-Tactin
uperﬂow Plus (Qiagen) for 1 h at 4 ◦C in binding buffer (0.5% Igepal,
50 mM NaCl, 50 mM Tris pH 7.5, 2 mM EDTA, 1x cOmplete Protease
nhibitor Cocktail Tablet (Roche)). Beads were washed in binding
uffer and eluted with NuPAGE LDS sample buffer and NuPAGE
educing agent (both Thermo). Start and unbound samples were
lso prepared. Bound proteins were separated using NuPAGE Midi
–12% SDS-PAGE gel (Thermo), stained with Safe Stain (Invitro-
en), bands corresponding to endogenous and Strep-V5-PCNA were
xcised and analysed by Mass Spectrometry as described previ-
usly [38]. Brieﬂy, gelbands were destained with 50% methanol in
% acetic acid before reduction (10 mM DTT), alkylation (50 mM
odoacetamide) and digest with Trypsin. Extracted peptides were
nalysed with a nAcquity (Waters) coupled Orbitrap Elite (Thermo)
C–MS/MS system. The peptide mixture was separated using a gra-
ient of 2–40% Acetonitrile in 0.1% formic acid. Precursors between
00 and 1500 m/z  were isolated with a mass window of 1.8 m/z and
nalysed after CID fragmentation in the ion trap with a normalized
ollision energy of 35%. RAW data was analysed with PEAKS (Bioin-
ormatics Solutions) version 7 using 10 ppm precursor and 0.5 Da
ragment mass accuracy. We  allowed to search for phosphoryla-
ion (S, T, Y), deamidation (N and Q) and oxidation (M) as variable
odiﬁcations and carbamidomethylation (C) as ﬁxed modiﬁcation.
eptide FDR was set to 1%.
.7. Recombinant protein production and puriﬁcation
Recombinant His-S-tagged PCNAWT and PCNAS228I were pro-
uced using pET30a, recombinant GST-PIP box fusions using
GEX4T-1 (GE Healthcare) and ‘3tag’ PCNAWT and PCNAS228I
ere produced using co-transfection of pEXP GST PCNAWT or
CNAS228I (pGEX6P-1, GE Healthcare), pRSFDuet-1 (Novagen) with
he S-tag exchanged for the AviTagTM (Avidity) sequence, express-
ng either His-PCNAWT and AviTagTM-PCNAWT or His-PCNAS228I
nd AviTagTM-PCNAS228I, and pBirA (Avidity) to biotinylate the
viTagTM during production. All plasmids were veriﬁed by
equencing. Proteins were expressed at OD600 ∼ 0.6-0.8 with
.1 mM IPTG at 25 ◦C for 5 h in E.coli BL21 codonplus (Novagen).
His-S-tagged PCNA was puriﬁed using Ni-NTA sepharose (QIA-
EN) and GST-PIP box fusions were puriﬁed using Glutathione
epharose 4B (GE Healthcare). ‘3tag’ PCNA was puriﬁed sequen-
ially using Ni-NTA sepharose, Glutathione sepharose and eluted
rom the column using PreScission Protease (GE Healthcare). All
roteins were further puriﬁed by Size Exclusion Chromatography
sing HiLoad 16/60 Superdex 200 or 75 (GE Healthcare) in HBS-EP
uffer as appropriate for Surface Plasmon Resonance.
Untagged PCNAS228I was generated using site directed muta-
enesis (QuikChange XL, Agilent Technologies) using previously
ublished untagged PCNA vector [7], conﬁrmed by sequencing.
ntagged PCNAS228I was expressed in E.coli BL21 Star (DE3) (Ther-
oFisher) using 1 mM IPTG at 18 ◦C for 16 h.
Protein puriﬁcation of untagged PCNAS228I for crystallography
ollowed Ludwig et al., 2010 [39] with modiﬁcations. For all steps,
ractions containing the protein were identiﬁed via SDS-PAGE anal-
sis. Pellets were harvested and resuspended to 0.1 mg/mL  in
0 mM Tris pH 8.0 and 50 mM NaCl, supplemented with cOm-
lete EDTA-free Protease Inhibitor Cocktail (Roche), 80 U/mL DNase
 (Sigma) and 0.25 mg/mL  Lysozyme (Sigma). Cells were lysed
ia cell disruption and cleared through centrifugation at 4 ◦C and
8000g for 1 h, the supernatant was ﬁltered and loaded on a pre-
quilibrated 5 ml  Ion Exchange Q FF column (GE Healthcare) using
n ÄKTA Puriﬁer system (GE Healthcare). The column was  washed
nd all bound proteins were eluted over a complex, 4-step gradi-
nt proﬁle: 5CV linear gradient from 50 mM NaCl (0% B) to 300 mM
aCl (27% B), followed by a 3CV gradient to 560 mM NaCl (54% B),pair 50 (2017) 22–35
then a 5CV linear gradient to 590 mM  NaCl (57% B), ﬁnishing with
a 5CV linear gradient to 1 M NaCl (100% B). Fractions containing
the protein were pooled and buffer exchanged to 30 mM NaOAc
pH 5.0 and 5 mM NaCl using a HiLoad 10/60 Desalting column. The
protein mixture was  then ﬂowed through a pre-equilibrated 5 ml
Ion Exchange Heparin column (GE Healthcare), to which PCNAS228I
did not bind. The Heparin ﬂow-through was  buffer exchanged to
20 mM Tris pH 8.0 and 50 mM  NaCl using a HiLoad 10/60 Desalt-
ing column, refocused by binding to a pre-equilibrated 5 ml Ion
Exchange Q FF column and eluted over 10CV a linear gradient to 1 M
NaCl. Protein eluate fractions were pooled and further puriﬁed by
Size Exclusion Chromatography, using a HiLoad 16/600 Superdex
200 column (GE Healthcare) equilibrated in 25 mM  Tris pH 8.0,
25 mM NaCl, 0.5 mM EDTA, 10% Glycerol. Fractions containing the
protein were pooled and concentrated to ∼6.65 mg/mL (monomer)
for crystallisation using an Amicon 50 kD MWCO  ﬁlter (Millipore).
2.8. GST pull downs
GST pulldown experiments were performed as previously
described [19] except recombinant proteins were puriﬁed prior
to the experiment. 10 g (or 100 g for weak binders as indi-
cated) GST-PIP fusions, 20 g His-S-PCNA or His-S-PCNAS228I
and 62.5 g BSA were combined in a buffer containing 100 mM
KH2PO4/K2HPO4. 10% was  removed as ‘start’, the rest incubated
with Glutathione sepharose 4B beads (GE Healthcare) for 2 h at 4 ◦C.
Beads were washed thoroughly, then boiled in Laemmli buffer. 10%
of input samples and 25% of bead samples were separated by SDS-
PAGE and stained with Coomassie. For western blotting, samples
were diluted 1:20, separated by SDS-PAGE, transferred to 0.2 m
nitrocellulose and probed for PCNA.
2.9. Surface plasmon resonance (SPR)
SPR was performed in two orientations using a Biacore T200
machine (GE Healthcare). For data in Fig. 3 and Supplementary
Fig. 2 ∼1000 Response Units (RU) GST-PIP fusions (ligand) were
bound to each lane of a CM5  S series chip (GE Healthcare) in acetate
pH 5.5 buffer using the Biacore immobilisation wizard with GST
as a control lane. Binding of the analytes, His-S-PCNA constructs,
was investigated using equilibrium of binding method in HBS-EP
buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.0005%
IGEPAL) with 1 g/l BSA, ﬁltered and de-gassed. The method used
240 s contact time followed by 600 s dissociation with low sam-
ple consumption setting and ﬂow rate of 20 l/min. A 10 point
2x dilution series from 12 M was  used including at least one
0 M sample, from low to high to low, repeating each concentra-
tion except 12 M.  Afﬁnity curves were plotted by subtracting RU
from the GST lane from the lane of interest and subtracting blank
analyte conditions, using Biacore T200 Evaluation software using
surface bound afﬁnity and steady state afﬁnity ﬁt options. Data was
collected at 10 Hz and equilibrium of binding was taken in a 5 s
window, 4 s before the injection stopped.
For reverse SPR (Supplementary Fig. 3), ∼1000 RU 3tag-PCNAWT
or PCNAS228I were immobilised on an SA S series chip (GE Health-
care) using SA immobilisation wizard. Binding of GST-PIP fusions
(analyte) was investigated using a Single Cycle Kinetics method
in HBS-EP with 1 g/l BSA, ﬁltered and de-gassed. The SCK method
consisted of 5 binding events of increasing concentration from a 2x
dilution series with one internal repeat (Cdt1, highest concentra-
tion 44.5 M)  or 10 binding events in two  5 step cycles with one
internal repeat (p21 highest concentration 27.9 M,  GST highest
concentration 53.2 M).  After each 5 step cycle was run, the same
cycle was repeated with buffer only. Contact time was  250 s, dis-
sociation time of 600 s, at 20 l/min with an additional 10 s buffer
contact and 1800s, 30 l/min dissociation after each 5 step cycle.
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Table 1
Data collection and reﬁnement statistics (molecular replacement). Numbers in
parentheses refer to the highest resolution shell.
hPCNAS228I (5MOM)
Data collection
Space group P 43 21 2
Cell  dimensions
a, b, c (Å) 162.95, 162.95, 140.40
,  ,  (◦) 90.00, 90.00, 90.00
Wavelength 0.9762
Resolution (Å) 89.07–2.27 (2.33–2.27)
Rsym or Rmerge 0.019 (0.122)
I/I 17.7 (1.5)
Completeness (%) 100.0 (100.0)
Redundancy 13.4 (13.2)
Reﬁnement
Resolution (Å) 89.07–2.27
No. reﬂections 87374
Rwork/Rfree 0.1987/0.2160
No Atoms
All (non-Hydrogen) 5731
Protein 5579
Solvent 152
B-factors
Protein 62.5
R.m.s. deviations
Bond lengths (Å) 0.008
Bond angles (◦) 1.126
Ramachandran Statistics
F
w
eR.H.C. Wilson et al. / D
ST and p21 cycles were run with an additional attempted ‘regen-
ration step’ of 30 s 100% ethylene glycol 30 l/min, high viscosity,
0 s stabilization. However, we could not ﬁnd suitable regeneration
onditions so data was only collected from fresh chips.
.10. Crystallisation, data collection and structure determination
Sitting drop, vapour diffusion crystallisation experiments were
et up in 96-well plates (Greiner) using a nanoliter Robot (Carte-
ian Technologies) [40]. Diffraction quality crystals in P43212 space
roup grew after 10 days at 20 ◦C, set up in a 1:1 protein:precipitant
olume ratio with well buffer containing 2 M (NH4)2SO4 and 0.1 M
aOAc pH 4.5. Crystals were cryo-protected using 20% (v/v) Ethy-
ene glycol in crystallisation buffer, before ﬂash-cooling in liquid
itrogen. Data up to 2.27 Å was collected on the i03 beamline at
he Diamond Light Source, Didcot, UK. Data was  processed and
caled using Xia2 [41] and the structure was solved by molecular
eplacement using PHASER [42] with the APO structure of wild-type
CNA as a search model (1VYM [43]), iterative rounds of manual
uilding with Coot [44] and reﬁnement using Phenix [45] with TLS
arameters, Secondary Structure and Non-Crystallographic Sym-
etry restraints. Structures were validated with MolProbity [46]
esulting in an overall score of 1.31 at 2.27 Å. Data collection and
eﬁnement statistics are detailed in Table 1, Protein Database Ref-
rence 5MOM.
. Results
.1. Cells from PARD affected individuals are more sensitive to the
CNA-interaction competitors T3 and T2AA
Many of the proteins that we identiﬁed as having altered inter-
ctions with PCNAS228I are involved in both DNA repair and DNA
eplication. While we found signiﬁcant repair deﬁciencies in cells
arrying the PARD mutation we did not identify any replication
elated defects. Therefore the weakened interactions that occur
n the PCNAS228I background must still be sufﬁcient to allow the
ssential activity of PCNA under unperturbed conditions. How-
ver, this generally reduced ability of PCNA to bind PIP box
ontaining proteins in PCNAS228I cells might mean that PIP-PCNA
nteractions in this genetic background would be particularly sen-
itive to additional competition. Two small molecule inhibitors of
IP-PCNA interactions have been previously reported: T3 (3,3′,5-
riiodothyronine) and T2AA (T2-aminoalcohol hydrochloride) [37].
tructural analysis showed that these two compounds interact with
CNA at the IDCL, blocking PIP binding. We  therefore hypothesised
hat PCNAS228I containing cells would be more sensitive to these
nhibitors.
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ig. 1. PCNAS228I cells are sensitive to increased competition for IDCL binding. Graphs s
ith  indicated concentrations of T3 (left) or T2AA (right) for three days. Data expressed as
xperiments, error bars are SEM, * p < 0.05, ** p < 0.005 using Student’s t-test.Favored (%) 97.42
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We assessed the sensitivity of EBV-transformed lymphoblasts
from four PARD-affected individuals (1504, 1505, 1506, 1779) and
two unaffected controls (0920, 0924) to T3 and T2AA using cell
proliferation assays, and found that all four PCNAS228I cell lines had
reduced growth in the presence of T3 and T2AA compared to WT
lines (Fig. 1). The differences between the genotypes are statisti-
cally signiﬁcant (p = 0.0091 at 100 M T3 and p = 0.024 at 20 M
T2AA). This implies that PCNAS228I-PIP interactions are already lim-
ited in an undamaged context and that increasing competition for
PCNA’s key binding site, the IDCL, is particularly toxic in this situ-
ation. We  note that the concentrations of T3 (a thyroid hormone)
used to inhibit PCNA-PIP interactions are at least a thousand fold
higher than the blood concentration in normal adults (equivalent
to 1.2–3 nM)  making it unlikely that the symptoms of PARD are
related to T3-dependent PCNA inhibition. However, these data do
suggest that cells from affected individuals are likely to be sensi-
tive to even transient and localised perturbations to PCNA client
binding events. This is the ﬁrst in vivo indication that some of the
symptoms of PARD might derive from a reduced ability of PCNAS228I
to function in a repair independent manner and this may  well con-
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ribute to the wide-ranging clinical manifestations of PARD. We
hus investigated the effect of PCNAS228I on a range of other PCNA
nteractors.
.2. The afﬁnities of PCNA-client interactions are reduced to
arying extents by the PCNAS228I change
To analyse the differences in the binding capabilities of PCNA
nd PCNAS228I we used a GST-PIP box pull down assay. As we pre-
ig. 2. The PCNAS228I mutation differentially affects PCNA binding to PIP box-containing
tudy.  GST represented by rectangle, PIP box sequences shown in red, mutated residues sh
ull  down of His-S-PCNAWT or PCNAS228I. Figure shows Coomassie stained gel of represe
:20  (bottom). Amount of ‘input’ loaded for Coomassie is equivalent to 1%, ‘Glut. beads’ 
re  indicated. C) Quantiﬁcation of binding. Histogram shows amount of PCNAS228I pulled 
n  = 1), DNMT1 (n = 3), Cdt1 (n = 6). Error bars are standard deviation. D) GST-PIP pull dow
sed  per condition. Coomassie as B, quantiﬁcation as C, n = 3.pair 50 (2017) 22–35
viously showed for Fen1, the PIP boxes of Cdt1 and DNMT1 are
severely reduced in their ability to bind PCNAS228I (Fig. 2). Given
our previous SILAC analysis of PCNAS228I interactions we  were
surprised that the DNMT1 binding was so dramatically affected,
as endogenous DNMT1 bound equally to PCNAWT and PCNAS118Icolumns [36]. This may  imply that additional binding sequences
are present in the full length DNMT1 protein or simply differences
in the experimental approaches used. We also observed reduced
binding of RNaseH2B, PolD3p66 and PolD4p12 PIP boxes to PCNAS228I
 proteins. A) Schematic showing GST-PIP peptide constructs generated during this
own in blue. Numbers relate to amino acid position in full length protein. B) GST-PIP
ntative pull down (top) and anti-PCNA western blot of the same samples diluted
(Glutathione sepharose 4B beads) is equivalent to 25%. Molecular weight markers
down relative to PCNAWT for indicated PIP constructs. Fen1 (n = 8), p21 (n = 8), p21*
n of His-S-PCNAWT or PCNAS228I for weak binders with 100 g GST-PIP construct
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riangle marker points; no binding of either PCNAWT or PCNAS228I to GST-p21* pept
elevant curves. ND = not determined.
lthough all are weak binders requiring 10-fold higher input of GST-
IP proteins to observe binding to PCNA WT (Fig. 2D). For RNaseH2B
nd PolD3p66 these data support our previous SILAC dataset [36],
nd in the case of RNaseH2B this also supports ITC data in a recent
aper from Duffey et al. [47]. However, the associations between
dt1, p21 or PolD4p12 and PCNAS228I were not determined in our
revious study, presumably due to their low abundance in undam-
ged asynchronous cell extracts.
In contrast to the other PIP boxes tested, the PCNA binding of
he p21-PIP-box is only minimally affected by PCNAS228I (Fig. 2B,
). This retained ability of p21 to bind PCNAS228I was also observed
sing ITC by Duffey et al. [47]. As with the other clients tested here,
he binding of the p21 PIP-box to both PCNAWT and PCNAS228I is
ediated by the canonical PIP-IDCL interface as both interactions
ere abolished when the key PIP-box residues (corresponding to
lu144, Phe150, Tyr151 in the full length protein) were mutated
o alanine (Fig. 2B). We  also used the GST pulldown approach to
est the binding of other PIP-boxes to PCNAS228I. However, we
aw no binding of GST-PIP fusion proteins derived from Cdc6, or
dt2 even to PCNAWT (Supplementary Fig. 1A, B). These PIP boxes
resumably comprise a sub-class with binding avidity below the
ensitivity threshold of our assay, or requiring speciﬁc buffer con-
itions (although we also tested these under the published buffer
onditions, Supplementary Fig. 1C) or additional binding motifs.
To obtain a quantitative measure of the effect of the PCNAS228I
utation on client protein binding we turned to surface plasmon
esonance (SPR). GST-PIP-box fusion proteins from Cdt1, DNMT1,
21, XPG, Lig1, and Fen1 were coupled to a CM5  chip, and the
inding of analyte PCNA (His-S-tagged, either WT  or S228I) was
ssessed. PCNAWT associated with all the GST-PIP-box fusion pro-GST-mutated p21 PIP peptide (GST-p21*) is also shown on the p21 graph (A) with
e was  observed. KD calculated from Biacore T200 evaluation software indicated on
teins, except that in which the interaction site had been mutated
(p21*) (Fig. 3, Supplementary Fig. 2). In all cases the afﬁnity of the
PCNA for the PIP-box fusions was  reduced by the PCNAS228I change
(Fig. 3), but the magnitude of these changes differed greatly; from
∼2 fold for the p21 PIP-box (KD increased from 1.8 M to 3.7 M)
to ∼14 fold for the Fen1 PIP-box (1.1 M to 15 M)  (Fig. 3A, B).
In fact, in most cases (Cdt1, XPG, DNMT1, Lig1) the binding of
PCNAS228I to the PIP-box fusions was  too low for a KD to be deter-
mined (Fig. 3C–F). Similar results were obtained when we coupled
biotinylated ’3-tag’-PCNA to a streptavidin coated chip surface and
used GST fused to the PIP-box from p21 or Cdt1 as the analyte. We
note that, in this orientation, the afﬁnity of PCNA for the p21 PIP
was only reduced 10% by the S228I change (Supplementary Fig. 3).
In many cases we  are able to detect low levels of PCNAS228I
binding to PIP-box fusion proteins by GST pulldown even when
the same interactions are not detectable by SPR. This is presum-
ably due to biophysical differences in assay format. By pulldown,
the interactions between PCNAS228I and the PIP-boxes of Cdt1 and
DNMT1, are low, but detectable above background (Fig. 2B, C and
Supplementary Fig. 1D), like XPG, Lig1 and Fen1 [36]. However, it
is clear that the striking effect of the PCNAS228I change is apparent
in both of these very different assays. We  note that in Xenopus cell
free extracts the binding of Cdt1 to PCNA has been suggested to
be dependent on DNA [48], however other data shows interaction
between recombinant Cdt1 and PCNA [13]. Here, the addition of
DNA to GST pull down assays had no effect on the Cdt1 PIP box pull
WT S228Idown of either PCNA or PCNA (Supplementary Fig. 1E).
These data demonstrate that the PCNAS228I variant affects all PIP
box-PCNA interactions tested. Importantly however, the binding of
p21 to PCNA is only minimally perturbed by PCNAS228I. Thus the
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ARD mutation has differential effects on PCNA’s ability to bind to
ts partner proteins.
.3. The IDCL structure of PCNA is perturbed by the S228I change
In none of the previously reported structures of PCNA bound
o client proteins does the interaction interface involve serine
28, the residue which is altered in PARD. These include struc-
ures of PCNAWT bound to p21 (1AXC and 4RJF), PolD3p66 (1U76),
en1 (1U7B and 1UL1), Pol (2ZVM), Pol (2ZVK), Pol (2ZVL),
NaseH2 B (3P87), p15PAF (4D2G), DVC1 (5IY4) and TRAIP (4ZDT)
7,15,49–55]. To explain how the disease causing mutation can
ave such dramatic effects on PCNA function via altered client
inding, we obtained a crystal structure of PCNAS228I at 2.27 Å
esolution (5MOM, Fig. 4A–D, Table 1). The overall structure of
CNA is retained by PCNAS228I, it is a recognisable toroidal trimer,
ith pseudo-6 fold symmetry and a central hole through which
ouble-stranded DNA will ﬁt (Fig. 4A). There is no evidence
f trimer destabilisation, as the monomer–monomer interface
ppears unperturbed when compared to published structures of
CNAWT. This is consistent with our previous work, as we did not
etect differences in trimer formation or stability [36]. Further-
ore, we do not observe reduced levels of PCNA in cells from PARD
ffected individuals (see Fig. 4E and Ref. [36]) and in the presence of
ycloheximide PCNAS228I appears to be as stable as the WT  protein
data not shown).
The structure is of sufﬁcient resolution that the electron density
f the isoleucine substitution can be identiﬁed (Fig. 4A). Compar-
son of this and the adjacent residues with the reported structure
f PCNAWT containing serine at this position (1VYM) provides a
lear mechanism for the defective interactions resulting from the
CNAS228I change. The larger isoleucine side chain has a steric clash
ith Tyr133 in the standard position, forcing a 90◦ rotation of the
idechain of Tyr133, which in turn repositions a signiﬁcant pro-
ortion of the IDCL (amino acids Gly127 to Asp120). The S228I
hange has very little effect on the overall structure and whilst
he total rmsd between our S228I structure and wild type struc-
ure is 0.6 Å, the local rmsd averaged over the three IDCL regions
residues 120–130) is 1.9 Å (Fig. 4B). Many of the residues of PCNA
hat are most affected by the S228I change coincide with those IDCL
esidues sitting at the interface between PCNA and PIP box con-
aining proteins, such as p21 (Fig. 4C) and Fen1 (Fig. 4D). Recently a
ighly similar structure of PCNAS228I was reported [47] and our data
onﬁrm those results. It thus appears that this dramatic structural
eorganisation of the IDCL, resulting from the single amino acid
hange in the PCNAS228I protein is likely to prevent this binding
urface from operating correctly. This provides a structural expla-
ation for the reduced binding of multiple PIP-boxes to PCNAS228I.
owever, it does not explain why p21 is less affected by this amino
cid substitution, which we explore later. We  next turned our atten-
ion to post translational modiﬁcations and whether these were
ffected by PCNAS228I.
.4. PCNAS228I is ubiquitinated after DNA damage
PCNA can be mono-and polyubiquitinated and SUMOylated
56–58]. The major post-translation modiﬁcation of PCNA in human
ells is mono-ubiquitination at Lys164, which is generated in
esponse to UV-damage by Rad6/Rad18 [59–61]. This modiﬁcation
s crucial for translesion synthesis and the tolerance of UV-induced
NA damage in replicating cells [62]. The position and surrounding
tructural context of Lys164 is unaltered by the PCNAS228I substitu-
ion, (Fig. 4A) suggesting that PCNAS228I likely remains competent
or ubiquitination. However, there are multiple PCNA-PIP box inter-
ctions that occur in the vicinity of DNA replication forks that can
nﬂuence PCNA ubiquitination and thus the PCNAS228I mutationpair 50 (2017) 22–35
could indirectly affect PCNA ubiquitination events. We  therefore
assessed the formation of UV-induced ubiquitinated PCNA in cells
from affected individuals and controls. We  observed a robust induc-
tion of ubiquitinated PCNA (for both WT  and S228I) across a range
of UVC doses (Fig. 4E) and recovery times (see Fig. 6) implying that
the ability to ubiquitinate PCNA is unaffected in PARD cells, and
cellular effects do not result from a defect in this pathway.
3.5. PCNAS228I does not remove a phosphorylation site
Given that the PCNAS228I alteration removes a serine from
PCNA which could potentially be phosphorylated we investigated
whether this site is a target for phosphorylation in PCNAWT. Using
a stably expressing Streptag-PCNAWT cell line we isolated PCNA
trimers, which will contain both tagged PCNAWT and untagged
endogenous WT  monomers, and performed MS analysis to detect
post translational modiﬁcations. We  found a number of mod-
iﬁcations including phosphorylation of Thr185 but no peptide
containing phosphorylation of S228 was  observed (Supplemen-
tary Figs. 4 and 5). Furthermore S228 is not reported modiﬁed
in the published databases such as Uniprot, PhosphoSitePlus, Pro-
teomics DB, or PHOSIDA. As we have not found any evidence of S228
being phosphorylated in our experiments or the public domain, it is
unlikely that the observed phenotypes of PCNAS228I are associated
with the elimination of a putative phosphorylation site. Together,
these data suggest that it is the direct structural alteration of the
IDCL region, rather than loss of a phosphorylation site that is the
molecular cause of the cellular defects underlying PARD. We  thus
went on to investigate the effect of the PCNAS228I mutation on
PCNA-client protein binding in more detail, and in particular the
differences between Fen1 and p21.
3.6. The residues of the p21 PIP box confer PCNAS228I resistant
binding
The interaction between p21 and PCNA is well characterised. In
the crystal structure of human PCNA with a 22 amino acid peptide
derived from p21 (1AXC), the PIP box and ﬂanking regions form an
expanded binding interface (>17 residues). p21-PCNA binding is
also reported to have the highest afﬁnity of any of the PCNA inter-
actions, in large part due to the interactions made by Tyr151 of the
p21 PIP box [49]. To identify the molecular determinants that allow
the p21 PIP box to retain binding to PCNAS228I we  performed GST-
PIP peptide pull downs using mutated versions of p21, and domain
swaps between the Fen1 and p21 PIP boxes and ﬂanking regions
implicated in PCNA binding (Fig. 5, Supplementary Fig. 6). A GST-
p21 PIP construct with Tyr151 mutated to phenylalanine (p21FF)
retained its ability to bind PCNAS228I to the same extent as p21 WT
(Fig. 5A). In addition, a Fen1 PIP box construct in which the Phe344
is changed to tyrosine (Fen1FY) did not restore the ability of the
Fen1-PIP to bind PCNAS228I (Fig. 5A). This suggests that the pres-
ence of a tyrosine at position 8 of the PIP box does not in itself
enable p21 to retain binding to PCNAS228I.
The high afﬁnity binding of p21 to PCNA has also been ascribed
to residues C-terminal to the PIP box in p21 which form a -sheet
with IDCL residues Met119 to Gly127 [15]. Fen1 in comparison is
unable to form this extensive -sheet [50]. N-terminal PIP ﬂank-
ing residues in p21 (speciﬁcally Ile255 to Ser261) also contact
PCNA through ionic interactions, but these are poorly ordered
so cannot be resolved to speciﬁc residues [15]. To examine the
impact of these regions on mediating interactions between p21 and
PCNAS228I we  constructed hybrid PIP-box GST fusion proteins com-
prising domain swaps between p21 and Fen1 and assessed their
PCNA binding capabilities by GST pull down (Fig. 5B). Exchanging
the p21 N-terminal ﬂank or the C-terminal ﬂank for that of Fen1
both slightly decreased the ability of p21-PIP to bind PCNAS228I
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Fig. 4. PCNAS228I alters PCNA function via structural changes at the IDCL. A) Apo structure of PCNAS228I (5MOM) shown in blue overlayed on apo PCNAWT [43] structure in
orange. The mutated I228 residues are shown as spheres. Top left inset zoomed area shows the rotation of Tyr133, propagating along the IDCL. Bottom left inset zoom shows
K164  and surrounding structural environment unchanged. Right panel shows the rotated view of the IDCL region highlighted in B, C, D below. B) Magniﬁed view of the IDCL
region  of a single monomer of PCNAS228I colour coded according to the heat map  of the rmsd between PCNAS228I (5MOM) and PCNAWT (1VYM). C) As B, but with residues
found  at the interface between PCNAWT and the p21 pip box (based on 4RJF) coloured in red. D) As C, but for the Fen1 PIP box (based on 4RJF), coloured in magenta. E) PARD
affected and control lymphoblasts were treated with the indicated doses of UVC and harvested after 7 h. Western blot shows induction of mono-ubiquitinated PCNAWT and
PCNAS228I.
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Fig. 5. The PIP-box motif is the major contributor which enables p21 binding to PCNAS228I. A) GST-PIP pull down of His-S-PCNAWT or His-S-PCNAS228I using wild type p21
and  Fen1, and constructs with mutated PIP position 8 residues. Figure shows Coomassie stained gel of representative pull down. Amount of ‘input’ and ‘Glut. beads’ as Fig. 2.
M AS228I
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s
r
f
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Polecular weight markers are indicated. Histogram (right) shows pulldown of PCN
en1FY (n = 2). Error bars are standard deviation. B) As A) except for single domain sw
waps. For histograms: all n = 3 except p21 and Fen1 n = 8.
elative to PCNAWT, but binding was still signiﬁcantly better than
or Fen1. Exchange of the p21 C-terminal ﬂank caused the slightly
arger of the two reductions but this region did not improve Fen1
inding to PCNAS228I (F F 21, Fig. 5B). Therefore, although both p21-
IP ﬂanking regions contribute to full binding of p21 to PCNAS228I,relative to PCNAWT for indicated PIP constructs. p21 and Fen1 (n = 8), p21FF (n = 4),
or histogram: all n = 3 except p21 and Fen1 n = 8. C) As A) except for double domains
they are not sufﬁcient for this ability. Even the exchange of both
p21-PIP ﬂanking regions alone or in combination with Tyr151Phe
did not reduce the ability of p21-PIP to bind PCNAS228I (F 21 F and F
21FF F, Fig. 5C). Therefore, the actual PIP-box sequence itself of p21
is the major factor enabling binding to PCNAS228I. Indeed, it is only
R.H.C. Wilson et al. / DNA Repair 50 (2017) 22–35 31
Fig. 6. PCNAS228I has subtle effects on cellular functions of PCNA. A) Example Western blots showing steady state levels of PCNA interacting proteins as indicated, also levels
of  PCNA and actin as a loading control. Histogram shows quantiﬁcation of p21 and Cdt1 levels relative to actin, shown relative to 0920 levels. n = 8 (0920, 0924), n = 7 (1504,
1505),  n = 6 (1506), n = 5 (1779). B) Example western blots showing degradation of Cdt1 and p21 at indicated times after 50 J/m2 254 nm UV exposure. Also levels of PCNA
and  actin as loading controls and appearance of ubiquitinated-PCNA at later time points. The graphs show quantiﬁcation of p21 and Cdt1 levels relative to actin, expressed
as  relative to time zero. n = 3 (1504, 1505, 1506, 1779), n = 5 (0920, 0924). C) Representative dot plots from 3 independent FACS analysis for indicated cell lines plotting DNA
content  (PI, x-axis) against BrdU (y-axis) to determine percentage in G1, S and G2 cell cycle phases. Graph (right) shows average cell cycle proportion for each cell line (error
bars  are SEM) and each genotype (WT  and S228I, error bars are STDEV).
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hen we exchanged the p21-PIP box for that of Fen1 (retaining p21
anking regions) that we signiﬁcantly reduced relative binding of
21 to PCNAS228I (21 F 21, Fig. 5C upper panel), and in parallel, when
e exchanged the Fen1-PIP box for that of p21 that we were able to
nduce signiﬁcant binding of Fen1 to PCNAS228I, comparable to that
f p21 itself (F 21 F, Fig. 5C lower panel).Thus although there is a
mall contribution from p21-PIP ﬂanking regions, the major deter-
inant of the ability to bind PCNAS228I lies within the 8 amino acid
IP box motif of p21.
.7. PCNAS228I has only a minor effect on the stability of Cdt1 and
21
In the last decade it has become clear that a unique class of
IP boxes, the PIP degrons, couple the binding of PCNA to protein
egradation in order to ensure regulated progression through the
ell cycle (reviewed in Ref. [63,64]). PIP degron motifs are simi-
ar to canonical PIP-boxes but they speciﬁcally contain a threonine
t position 5, aspartic acid at position 6 and a positively charged
esidue at position +4 (C-terminal) [48]. The targeted proteaso-
al  degradation of PIP-degron containing client proteins following
inding to PCNA is achieved through recruitment of the Cdt2CRL4
biquitin ligase complex (reviewed in Ref. [63,64]), either after
NA damage or on entry into S-phase. Client proteins containing
IP degrons include p21, the pre-replication complex component
dt1, and the histone methyltransferase Set8 [13,65–76]. PolD4p12,
 component of the Pol	 holoenzyme; Cdc6, a component of the
re-replication complex; and the translesion synthesis polymerase
ol are also suggested to contain PIP-degrons [77–81].
We have shown that the interaction between Cdt1 and PCNA is
erturbed in vitro by the S228I mutation, while the p21 interaction
s relatively unaffected (Figs. 2 and 3). We  thus hypothesised that
dt1 might be less well targeted for appropriate degradation in cells
arrying PCNAS228I whereas p21 degradation might be unaffected
r even increased due to reduced competition for PCNA binding.
o assess this we  ﬁrstly determined the steady state levels of these
roteins in cells from PARD-affected individuals and controls. How-
ver, we do not ﬁnd signiﬁcant differences in the steady state levels
f Cdt1 or p21 that are consistent across genotypes. We  note that
here is a small tendency for increased Cdt1 and for reduced p21
evels in PARD cell lines (Fig. 6A), however the biological signiﬁ-
ance of this is not yet clear. We  did not observe any other steady
tate differences in any other PCNA client proteins tested (Fig. 6A).
The PCNA-mediated degradation of Cdt1 and p21 is induced
fter UVC treatment [65,67]. Thus we analysed the decrease in
he levels of these proteins after UVC irradiation of cells carrying
CNAS228I and PCNAWT. In all cell lines Cdt1 was degraded more
apidly than p21 (Fig. 6B), as previously reported [82]. Remark-
bly considering the large differences in binding afﬁnities from
ur in vitro work, we do not observe dramatic alterations in the
ate of Cdt1 or p21 degradation that is consistent across genotype.
Fig. 6B). It is of note that multiple mechanisms control Cdt1 levels
o prevent re-replication, including a pathway of Cdt1 degradation
tilising the SCFSkp2 ubiquitin ligase complex [73]. It is therefore
ossible that we do not observe dramatically slower Cdt1 degra-
ation in PCNAS228I cells because redundant mechanisms operate
o ensure the timely destruction of this crucial replication control
actor. Alternatively, these data may  suggest a strong robustness
n (at least) some of the activities of PCNA if the residual binding
f Cdt1 to PCNAS228I is still sufﬁcient to ensure timely degradation.
his interesting scenario will be the focus of further work.
Lastly we show small but consistent differences in cell cycle
hase distribution between PCNAS228I and WT  control lym-
hoblasts. Representative data are shown in Fig. 6C with summary
raph from three experiments. PCNAS228I lymphoblasts show a
light reduction in G1 and increase in both S and G2 popula-pair 50 (2017) 22–35
tions (Fig. 6C). This might suggest some reduced ability to progress
through S-phase but requires further investigation in a more
tractable system. Interestingly, we  did not observe such alterations
in cell cycle phase distribution when using primary ﬁbroblasts from
affected individuals and controls [36]. We hypothesise that the low
proliferation rate of these primary ﬁbroblasts masked the S phase
dependent effects that we  now observe.
Here we have shown that the PCNAS228I mutation has impli-
cations for PCNA-binding events that are not related to DNA
repair. We  have identiﬁed DNMT1, Cdt1, RNaseH2B, PolD3p66 and
PolD4p12 as PIP box containing proteins that are affected in their
ability to bind to PCNAS228I, and provided a structural explanation
for the reduced binding capability of PCNAS228I. The p21 PIP box
has an unusual property in that it is able to bind with relatively
normal afﬁnity to PCNAS228I and we  have demonstrated that this
ability is derived from the PIP box itself. In spite of the dramatic
effects on in vitro PCNA binding events caused by PCNAS228I the
cellular phenotypes of this mutation are only subtle. Nevertheless,
cells from individuals affected by PARD are sensitive to the PCNA
inhibiting compounds T3 and T2AA and have consistent differences
in cell cycle phase distribution. These effects should be considered
in attempts to explain the etiology of PARD.
4. Discussion
4.1. Competition between PIP-box containing proteins for PCNA
binding
The interaction between PCNA and many of its client proteins is
extremely well characterised at the structural level with more than
70 crystal structures, from more than 10 species, deposited in the
PDB. However, the sheer number of proteins reported to be able to
interact with PCNA, the trimeric nature of the PCNA ring, and the
dynamic and competitive nature of the binding events mean that
there is a much more limited in vivo understanding of the precise
role that PCNA plays in dynamically regulating essential activities
during replication and repair. The identiﬁcation of the PCNAS228I
mutation in a human population has therefore given us a unique
opportunity to investigate the in vivo role of PCNA in human cel-
lular activities. The S228I alteration causes dramatic reductions in
the binding abilities of most client proteins in vitro and yet the
cellular phenotypes appear to remain relatively subtle. This sug-
gests that, in the competitive nuclear environment, even reduced
binding afﬁnities are sufﬁcient to drive essential interactions with
PCNA. Of course, if all PCNA-PIP interactions are equally perturbed
by the S228I mutation then, in a competitive environment with
sufﬁciently high concentrations of client proteins, there might be
relatively little alteration to the relative ﬁnal binding proﬁle: the
reduced afﬁnity interactions would all occur in the circumstances
of reduced competition. This might account for the ability of the
PCNAS228I cells to survive in the face of an apparently dysfunctional
PCNA. We have already commented that the structural organisa-
tion of replication factories, providing high local concentrations of
PCNA, can also go some way towards accounting for the relatively
speciﬁc effect that the S228I mutation has on repair, as opposed to
replicative functions [83].
However, it is important to note that the S228I mutation does
not affect all PCNA-PIP box interactions equally. Notably the p21 PIP
box seems relatively blind to the effect of this amino acid change.
p21 is reported to have one of the highest afﬁnities for PCNA,
suggesting that the p21-PCNA interaction has evolved to outcom-
pete alternative PIP-mediated protein binding events. In PCNAS228I
cells the reduced afﬁnity for other PIP-box proteins would mean
that p21 is even more likely to gain control of the PCNA bind-
ing interface. Ectopic expression of high afﬁnity, non-degradable
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IP-box-containing fusion proteins or peptides perturbs the equi-
ibrium of PCNA interactions and has profound effects on cell
roliferation [84,85]. Of course, p21 contains a PIP degron and nor-
ally the PCNA associated p21 is efﬁciently degraded, clearing the
ay for subsequent association of the next client protein. We  have
hown that p21 degradation is operational in PCNAS228I cells, and
his should help to mitigate the consequences that would otherwise
rise from a hypercompetitive PCNA binder.
.2. p21 retains binding to PCNAS228I
p21 makes extensive contacts with PCNA using regions ﬂank-
ng the PIP-box, however our results from Fen1 and p21 domain
wap experiments show that the retained ability of p21 to bind
o PCNAS228I is mostly derived from the PIP box itself. It is as yet
nclear whether it is particular residues at speciﬁc positions within
he PIP-box or the combination which is important for this ability.
21 is a PIP-degron, however the TD that is part of the PIP-degron
otif in p21 cannot be responsible since it is also found in Cdt1,
he binding of which is affected by the S228I mutation. Compar-
ng the PIP box sequences of the proteins that we have tested, it
s only the methionine at position 4 which is unique in p21, and
hus which represents a good candidate for mediating this bind-
ng activity. In the crystal structure of the p21 PIP with PCNA, this
ethionine (Met147) is not reported to form speciﬁc interactions
ith PCNA [15], but it is possible that a methionine at this position,
erhaps in combination with the other p21 speciﬁc residues, gen-
rates a PIP box with the speciﬁc attributes that enable binding to
he abnormal IDCL of PCNAS228I.
.3. Different classes of PIP-boxes
In our hands GST-PIP peptides from two reported PCNA-
nteracting proteins (Cdc6 and Cdt2), did not interact with PCNA in a
ST-pulldown assay, even when assayed using the same buffers as
reviously published experiments. These proteins may  form a sep-
rate class of PCNA binders that either require additional sequences
ot included in our GST-PIP constructs (-12, +9 residues) or binding
evels may  be below the level of detection in this assay but might
e revealed in other less stringent assays. Alternatively, these pro-
eins may  require PCNA bound to chromatin for successful binding,
r post-translational modiﬁcations, for example pol binds prefer-
ntially to mono-ubiquitinated PCNA [61].
.4. PCNA-associated repair disorder
The data presented here, and in our previous work, show that the
ramatic deﬁciencies in client protein binding caused by the S228I
utation in vitro do not result in comparably dramatic cellular phe-
otypes. This indicates that PCNA functions in cells are impressively
obust, able to operate even if binding afﬁnities are dramatically
educed. However, there are some important consequences of
his mutation because PARD has severe clinical phenotypes. Cells
erived from individuals affected by PARD are more sensitive to
V irradiation, and show reduced unscheduled DNA synthesis and
ecovery of RNA synthesis after UV [36]. These defects in NER are
ikely linked to the disrupted binding of PCNAS228I to the key NER
actor XPG, as well as possibly Lig1 and Fen1 which are also impli-
ated in excision repair processes. The fact that cells with PCNAS228I
how increased sensitivity to PCNA inhibition, and an altered cell
ycle proﬁle also implies that the reduced afﬁnity of PCNAS228I for
ts clients can manifest as consequences in undamaged cells. It cer-
ainly seems likely that, occasionally during cellular replication,
here will be a relative imbalance in PCNA client availability, which
ill then be particularly problematic when PCNA’s binding ability
s compromised by S228I. In a similar fashion, the subtle effectspair 50 (2017) 22–35 33
seen on PIP degron proteins may  result in occasional errors in con-
trolling entry into S phase. Such rare stochastic failures in PCNA
function may  not have dramatic consequences for cells in culture,
but a consideration of such events will certainly be important as
we try to understand the development and clinical manifestations
of the PCNA associated repair disorder.
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